|Awarded On||February 21, 2019|
|Title||Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma|
|Award Mechanism||Individual Investigator Research Awards for Clinical Translation|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Cassian Yee|
|Cancer Sites||Eye and Orbit, Skin|
*Pending contract negotiation
Uveal melanoma (UM) is the most common cancer of the eye in adults and, in its advanced stages, is resistant to conventional therapy. Adoptive Cellular Therapy (ACT) is a promising treatment option that uses the patient’s own immune system cells to treat cancer. ACT involves the isolation and expansion of cancer-specific immune cells (T cells) that are infused into patients. These T cells can then go to tumor sites, kill cancer cells, and potentially provide a long-lasting response that protects against recurrence of the cancer. We have developed a form of ACT known as endogenous T cell (ETC) therapy. In ETC, cancer-specific T cells are isolated from the patient’s blood and grown in the lab ...